Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Xeraya Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Xeraya Capital

Xeraya Capital

Operating

Xeraya Capital: A global venture capital firm investing in life sciences, biotech, and medical technologies.

Location
Kuala Lumpur, Kuala Lumpur, MY
Founded
2012
Firm
Compare
Portfolio
Employees
Website

Investments

OncoMyx Therapeutics
OncoMyx Therapeutics

Total Raised

$50M

Rounds

1

Series B$50MDecember 2021
Viron
Viron

Total Raised

$81M

Rounds

3

Series B$50MDecember 2021
Series A$25MJune 2019
InterVenn Biosciences
InterVenn Biosciences

Total Raised

$278.1M

Rounds

5

Series B$34MNovember 2020
Rapid Micro Biosystems
Rapid Micro Biosystems
Public

Total Raised

$377.4M

Rounds

12

Private Equity$120MMay 2020
Private Equity$60MMay 2018
Aria CV
Aria CV
Acquired

Total Raised

$53.7M

Rounds

6

Series B$31MFebruary 2020
P2 Science
P2 Science

Total Raised

$26.6M

Rounds

11

Series C$12MJanuary 2020
Series B$9.6MMarch 2017
Acutus Medical
Acutus Medical
Acquired

Total Raised

$343.2M

Rounds

10

Series D$100MJune 2019
Series C$75MMarch 2016
Liquidia
Liquidia
Public

Total Raised

$415.9M

Rounds

20

Series D$25.5MFebruary 2018
ViewRay
ViewRay
Public

Total Raised

$877.8M

Rounds

22

Post Ipo Equity$14MAugust 2016
Post Ipo Equity$26.7MJuly 2015
Iconic Therapeutics
Iconic Therapeutics
Acquired

Total Raised

$82.8M

Rounds

12

Series C$10MAugust 2016
Boston Neurosciences
Boston Neurosciences

Total Raised

$10M

Rounds

2

Series A$10MOctober 2015
Gevo
Gevo
Public

Total Raised

$578.7M

Rounds

20

Series D$32.6MMay 2010